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Abstract The complications of long-term levodopa
therapy for Parkinson’s disease (PD) include motor fluc-
tuations, dyskinesias, and also nonmotor fluctuations—at
least equally common, but less well appreciated—in
autonomic, cognitive/psychiatric, and sensory symptoms.
In seeking the pathophysiologic mechanisms, the leading
hypothesis is that in the parkinsonian brain, intermittent,
nonphysiological stimulation of striatal dopamine receptors
destabilizes an already unstable system. Accordingly, a
major goal of PD treatment in recent years has been the
attainment of continuous dopaminergic stimulation
(CDS)—or, less theoretically (and more clinically verifi-
able), continuous drug delivery (CDD). Improvements in
the steadiness of the plasma profiles of various dopami-
nergic therapies may be a signal of progress. However,
improvements in plasma profile do not necessarily translate
into CDS, or even into CDD to the brain. Still, it is reas-
suring that clinical studies of approaches to CDD have
generally been positive. Head-to-head comparative trials
have often failed to uncover evidence favoring such
approaches over an intermittent therapy. Nevertheless, the
findings among recipients of subcutaneous apomorphine
infusion or intrajejunal levodopa/carbidopa intestinal gel
suggest that nonmotor PD symptoms or complications may
improve in tandem with motor improvement. In vivo
receptor binding studies may help to determine the degree
of CDS that a dopaminergic therapy can confer. This may
be a necessary first step toward establishing whether CDS
is, in fact, an important determinant of clinical efficacy.
Certainly, the complexities of optimal PD management,
and the rationale for an underlying strategy such as CDS or
CDD, have not yet been thoroughly elucidated.
Keywords Parkinson’s disease  Motor complications 
Nonmotor fluctuations  Continuous drug delivery
Introduction
In patients with Parkinson’s disease (PD), both motor and
nonmotor complications are common, burdensome seque-
lae of long-term levodopa treatment. The motor compli-
cations are well recognized. In broad terms, they consist of
motor fluctuations and dyskinesias, although within each of
these categories varied patterns have been described
(Olanow et al. 2009). By some estimates, more than 50 %
of PD patients report one or another such problem after
5 years of levodopa use; and after 10 years, up to 80 % of
patients report them (Obeso et al. 2000). Their impact can
be substantial, reducing the patient’s mobility and the
ability to perform activities of daily living (ADL). In
addition, emotional well-being and health-related quality
of life (HRQoL) can be severely impaired (Chapuis et al.
2005; Damiano et al. 2000).
The nonmotor complications are fluctuations resulting in
symptoms such as mood disturbance, cognitive dysfunc-
tion, dysautonomia, and pain (Witjas et al. 2002). Con-
sidered together (Chaudhuri et al. 2011), they may be at
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least as common as motor complications (Gunal et al.
2002), but they appear to be under-reported (Chaudhuri
et al. 2010). In a survey of PD patients with motor fluc-
tuations (Witjas et al. 2002), 100 % of participants reported
nonmotor fluctuations, which 28 % rated as being more
disabling than the motor problems. Anxiety, excessive
sweating, slowed cognition, fatigue, and akathisia were the
most frequent nonmotor fluctuations reported. The burdens
imposed by such fluctuations are hard to differentiate from
those imposed by PD itself. Still, in a recent large-scale
study of the overall nonmotor burden (Martinez-Martin
et al. 2011), total score on the nonmotor symptoms scale
(NMSS) (Martinez-Martin et al. 2009) showed a high
correlation with HRQoL (r = 0.70), as measured by the
39-item PD questionnaire (PDQ-39) (Jenkinson et al.
1997a). Remarkably, the correlation exceeded that for
motor dysfunction (r = 0.58), as measured by scales for
outcomes in PD (SCOPA) motor score (Martı´nez-Martı´n
et al. 2005).
Numerous studies have investigated the predictors and
potential pathophysiologic mechanisms of levodopa com-
plications in PD patients, in hope of developing clinical
strategies to avoid them. For motor complications, espe-
cially dyskinesia, the reported risk factors include higher
dosage and longer duration of levodopa treatment, longer
duration and severity of a patient’s PD, and younger age at
PD onset (Grandas et al. 1999). Although nonmotor PD
manifestations may be related to nondopaminergic brain
changes concomitant with or secondary to the striatal
dopaminergic deafferentation considered to be a PD hall-
mark (Simuni and Sethi 2008), at least some nonmotor
fluctuations (e.g., in autonomic function) have likewise
been associated with higher dosage and longer duration of
levodopa treatment and with younger age at PD onset
(Chaudhuri and Schapira 2009; Gunal et al. 2002). In a
survey of patients with motor fluctuations, all 50 subjects
reported nonmotor fluctuations, most of which occurred in
the patients’ ‘‘OFF’’ state, thereby exhibiting correlation
with their motor dysfunction (and with time spans of
levodopa inefficacy) (Witjas et al. 2002). However, non-
motor fluctuations of all types (e.g., autonomic, cognitive/
psychiatric, or sensory) are also seen during ‘‘ON’’ time
(Gunal et al. 2002).
Extensive preclinical research, e.g., in primate PD
models (Jenner 2009), has been advancing the hypothesis
that the motor complications of chronic levodopa therapy
may derive from the therapy’s intermittent, nonphysiolog-
ical stimulation of the parkinsonian brain’s striatal dopa-
mine receptors (Chase et al. 1989; Grace 2008; Jenner 2008;
Nutt et al. 2000; Olanow et al. 2006). On this basis, a major
goal of PD treatment in recent years has been the attainment
of continuous dopaminergic stimulation (CDS)—or, less
theoretically (and more clinically verifiable), continuous
drug delivery (CDD). Pharmacologically, CDD has been
attempted by strategies including a variety of levodopa
formulations and delivery methods, as well as by dopamine
agonists with differing pharmacokinetic properties and
receptor-affinity profiles. This review will survey the key
therapeutic advances.
Defining the complications
Among the complications of chronic levodopa therapy in
PD, motor fluctuations (Olanow et al. 2009) are defined as
alterations between periods of clinical response of motor
symptoms to levodopa, during which the patient’s mobility
and motor function are relatively good (i.e., during ‘‘ON’’
time), and periods when motor response deteriorates
(‘‘OFF’’ time). In early PD, such oscillations are not
expected to occur. At this stage of the disease, the motor
response to a single levodopa dose is typically long-lasting
([4 h), despite the drug’s plasma half-life of only
60–90 min, yielding a span of ‘‘ON’’ time sufficient to
bridge the interval between successive doses throughout
the patient’s waking day. Indeed, response is often stable
even if one or more doses are missed (‘‘long-duration
response’’). With advancing PD, however, the duration of
motor-symptom control conferred by a levodopa dose
progressively shortens toward an approximate matching of
the drug’s plasma half-life (‘‘short-duration response’’).
Patients may then begin to experience a predictable
‘‘wearing-off’’ effect. Patients may also have rapid,
unpredictable fluctuations between ‘‘ON’’ and ‘‘OFF’’
states (‘‘ON–OFF phenomenon’’) (Marsden and Parkes
1976), and some doses may take longer to become effec-
tive (‘‘delayed-ON’’) or may not be effective at all (‘‘no-
ON’’) (Obeso et al. 2008). Although it has been hypothe-
sized that motor fluctuations might arise in advanced PD
because loss of dopaminergic presynaptic terminals may
decrease striatal capacity to store dopamine, ‘‘wearing-off’’
has also been seen in PD treated with apomorphine and
other dopamine agonists not stored in dopaminergic ter-
minals (Bravi et al. 1994). The implication is that the
pathophysiology of motor fluctuations must have postsyn-
aptic facets (Verhagen Metman et al. 1997).
Dyskinesias in PD patients reliant on chronic levodopa
(Olanow et al. 2009) are involuntary movements most
typically coinciding with maximum levodopa plasma level
and maximum motor-symptom response (‘‘peak-dose dys-
kinesia’’). In such patients, the dyskinesia is typically
choreiform, involving any part of the body, but may be
dystonic or myoclonic. Dyskinesia can also occur when an
‘‘ON’’ state begins and again as it ends (‘‘diphasic dyski-
nesia’’). In such patients, the abnormal movements tend to
be rhythmic, stereotypic, and asymmetric, and to affect the
K. R. Chaudhuri et al.
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legs. In either case, the dyskinesia has long been viewed as
the expression of a disruption of the normal ability of the
basal ganglia to select and execute motor programs
(Marsden 1982).
With increasing appreciation of the complexity of the
dopaminergic influence on basal ganglia function, there has
come a more specific suspicion that dyskinesia may be the
eventual outcome of a fundamental inadequacy of standard
levodopa as an exogenous replacement for endogenous
dopamine, namely the treatment’s abnormally pulsatile
stimulation of striatal dopamine receptors (Jenner 2008;
Olanow and Obeso 2000). The physiologic stimulation of
these receptors appears to be a tonic process with phasic
fine-tuning (Goto et al. 2007; Schultz 1994), requiring that
the striatum maintain a steady baseline supply of endoge-
nous dopamine (Venton et al. 2003). Hence, the institution
of abnormally pulsatile stimulation is thought to lead to
dysregulation of genes and proteins in striatal neurons, in
turn, producing an enduring alteration of firing patterns in
basal ganglia output neurons (Jenner 2008; Olanow and
Obeso 2000). In brief, the intermittency of standard levo-
dopa therapy does not achieve the desired normalization of
the parkinsonian basal ganglia but instead destabilizes the
already unstable system (Olanow et al. 2009). Indeed, in
PD models such as the primate models induced by the
dopamine-neuron-specific neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), intermittent adminis-
tration of short-acting dopaminergic agents (e.g., levodopa)
has been found notably apt to induce dyskinesia (Pearce
et al. 1998); yet even the short-acting agents have been
found not to do so if they are given continuously (Bibbiani
et al. 2005).
The nonmotor fluctuations seen during long-term levo-
dopa usage in PD have been categorized as dysautonomic,
cognitive/psychiatric, and sensory (Witjas et al. 2007).
Although their causes remain obscure, dopaminergic dys-
function would appear to be involved, acting either directly
or through the unbalancing effects of dopaminergic dys-
function on other neurotransmitter systems (Witjas et al.
2007). As a possible example of a direct link, neuroimag-
ing data have identified dopaminergic dysfunction (reduced
receptor availability) in the hypothalamus of the parkin-
sonian brain (Politis et al. 2008), an abnormality conceiv-
ably influencing dysautonomia. As a possible example of
an indirect link, neuroanatomic and neurophysiologic data
have combined in suggesting that in the normal brain,
dopaminergic and serotonergic systems interact via reci-
procal connections between the substantia nigra (and ven-
tral tegmental area) and the brainstem raphe´ nuclei
(Di Giovanni et al. 2008), conceivably affecting sleep
homeostasis. For either direct or indirect linkage of dopa-
minergic dysfunction to nonmotor fluctuations, the fluctu-
ations might be responsive to CDD. However, it may be
instructive that in advanced PD, deep brain stimulation of
the subthalamic nucleus appears to best alleviate nonmotor
fluctuations affecting sensory, autonomic, and cognitive
function, while neuropsychiatric fluctuations respond less
consistently (Witjas et al. 2007).
The evolution of CDD strategies
Because of a number of pharmacokinetic factors, intermit-
tent oral dosing of levodopa does not provide stable plasma
drug levels. The most significant problems are the short
half-life of levodopa (*60 min) (Deleu et al. 2002) and the
pulsatile and unpredictable absorption of levodopa from the
small intestine due to erratic gastric emptying (Kurlan et al.
1988; Nyholm et al. 2003). As efforts to improve the agent’s
solubility so as to enhance its absorption, levodopa has been
studied as an orally administered liquid or methyl ester
(Antonini et al. 2010a). Brain levodopa levels also vary
owing to competition of levodopa with amino acids for
transport across the intestinal wall and the blood–brain
barrier (Frankel et al. 1989), but these perturbations are
relatively minor and in most patients appear not to have a
clinically relevant impact (Nutt et al. 1989).
Efforts to achieve a steady level of levodopa, or of
dopaminergic PD therapies in general, began almost at the
inception of the treatments themselves (Tolosa et al. 1998).
Inhibition of levodopa metabolism was first attempted in
the 1960s, using the peripheral dopa decarboxylase inhib-
itor (DDI) benserazide or subsequently, carbidopa. Then, in
the early 1970s, a sustained-release oral formulation of
levodopa was developed. Dopamine-receptor agonist
therapies were tested as early as 1951 but did not become
an option in routine PD treatment until the 1970s, when an
oral formulation of bromocriptine was introduced. Con-
tinuous infusion of a dopaminergic therapy was first
attempted in the mid 1970s, using intravenous delivery. All
of these broad strategies continue to be developed.
Oral levodopa in combination with metabolic inhibitors
Dopamine does not cross the blood–brain barrier. By
contrast, levodopa does cross the barrier, provided that it
has not been converted to dopamine in the periphery.
Within the central nervous system (CNS), dopaminergic
neurons can perform this conversion. In view of these
circumstances, the CNS bioavailability of levodopa, and of
dopamine as its desired CNS metabolite, can be enhanced
by a number of strategies (Deleu et al. 2002): (1) blocking
the peripheral conversion of levodopa into dopamine or
another metabolite, (2) blocking the central metabolism of
levodopa along pathways that do not produce dopamine,
and (3) blocking the central metabolism of dopamine.
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Dopa decarboxylase inhibitors, such as carbidopa or
benserazide, are given to implement the first of these
strategies, i.e., they block the peripheral conversion of
levodopa into dopamine, allowing a larger influx of levo-
dopa into the brain. By doing so, they permit reduction of
total daily levodopa dosage (Cedarbaum 1987). They also
reduce levodopa side effects arising from peripheral
dopamine-receptor stimulation (e.g., nausea and vomiting)
(Kaakkola et al. 1985; Markham et al. 1974). Pharmac-
okinetically, they increase the peak plasma levodopa con-
centration (Cmax), increase overall levodopa exposure [area
under the concentration–time curve (AUC)], and prolong
levodopa plasma half-life (Cedarbaum 1987; Robertson
et al. 1989). In clinical practice, levodopa is invariably
combined with carbidopa or benserazide, regardless of
other strategies that may also be employed to enhance
levodopa availability.
Catechol-O-methyltransferase (COMT) inhibitors imple-
ment the first and perhaps also the second and third strategy,
depending on whether the drug can enter the brain. Via
COMT inhibition, each such drug blocks the conversion of
levodopa into 3-O-methyldopa or 4-O-methyldopa and also
of dopamine to 3-methoxytyramine (Deleu et al. 2002).
However, entacapone acts only in the periphery, while
tolcapone may have some central effect. On the other hand,
tolcapone is associated with liver toxicity and is recom-
mended only for motor complications not responsive to
other levodopa adjuncts (and even then only with regular
monitoring of liver function) (Tasmar 2009). Pharmac-
okinetically, single-dose entacapone has been found to
increase the AUC and prolong the plasma half-life of
levodopa administered as an immediate-release (IR) for-
mulation, without affecting levodopa Cmax (Nutt 1996,
2000). With repeated entacapone dosing, both peaks and
troughs in levodopa plasma level become higher, with
diminished difference between them (Fig. 1) (Nutt 1996).
This leveling, however, is not as pronounced as may be
achieved by levodopa administered as a controlled-release
(CR) formulation (LeWitt et al. 2009). Pharmacokinetic-
pharmacodynamic studies (Merello et al. 1994; Piccini et al.
2000; Ruottinen and Rinne 1996a, b) have shown that an
increase in the AUC of levodopa administered with ent-
acapone is temporally associated with improved motor
function. This benefit, however, may be achieved at a cost
of increased dyskinesia (Stocchi et al. 2010).
Monoamine oxidase (MAO) inhibitors implement the
third strategy: i.e., they block the conversion of CNS
dopamine into 3,4-dihydroxyphenylacetic acid (Deleu et al.
2002). Of the two known MAO isoforms, MAO-A pre-
dominates in the intestinal tract while MAO-B is prominent
in brain areas including the basal ganglia (Youdim and
Bakhle 2006). Two drugs, rasagiline and selegiline (Azi-
lect 2009; Eldepryl 2011), are currently marketed as
irreversible MAO-B-selective inhibitors. Both are approved
as adjunctive therapy to levodopa, and rasagiline is also
approved as monotherapy in early PD. In general, MAO-B
inhibitors improve ‘‘ON’’ time only modestly (Rascol et al.
2005), suggesting that patients may continue to experience
motor and nonmotor fluctuations.
Controlled-release levodopa
Slow-release formulations of orally administered levodopa
are available only in combination with a DDI (carbidopa in
the United States and benserazide or carbidopa in the
European Union). Madopar HBS (hydrodynamically
balanced system; Roche Products, Ltd, Hertfordshire, UK)
combines levodopa and benserazide in a capsule that forms
a mucoid body, which in turn remains in the stomach for a
prolonged period, allowing slow diffusion of its contents
(Erni and Held 1987). Sinemet CR (Merck & Co., Inc.,
Whitehouse Station, NJ; Bristol-Myers Squibb Company,
Princeton, NJ) combines levodopa and carbidopa in a
monolithic-matrix tablet that releases the drugs gastroin-
testinally, via surface dissolution and erosion (Dempski
et al. 1989; Wilding et al. 1991). In general, slow-release
formulations may permit a decrease in dosing frequency
and may reduce the temporal variability in levodopa
plasma level (Fig. 2a), compared with levodopa in its
standard IR form (Cedarbaum et al. 1989; Pahwa et al.
1997). Moreover, pharmacodynamic studies in advanced
PD have reported clinical benefits (Fig. 2b), including an
increase in ‘‘ON’’ time (Cedarbaum et al. 1989; Pahwa
et al. 1997). However, slow-release formulations also delay
the levodopa plasma Cmax (*2 h vs. 30–45 min for IR
formulations) and may exhibit a lower level at the maxi-
mum, necessitating an increase in total daily levodopa
Fig. 1 Plasma levels of immediate-release oral levodopa with versus
without entacapone in a PD patient receiving treatment (arrowheads)
every 2 h (data adapted from Nutt 1996)
K. R. Chaudhuri et al.
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dosage (Pahwa et al. 1997; Sage and Mark 1994). A major
problem is that erratic pharmacokinetics may result in
unpredictable clinical response. Moreover, patients on
slow-release formulations often require a morning dose of
an IR formulation. A new oral levodopa–carbidopa for-
mulation combining the pharmacokinetics of IR and CR
formulations has shown promise in clinical trials (Hauser
2012) and awaits FDA approval.
Dopamine-receptor agonists
Dopamine-receptor agonists are indicated as monotherapy
in early PD and as adjunctive therapy to levodopa at all
stages of PD. Despite the gold-standard status of levodopa
for controlling motor symptoms, the agonists have poten-
tial advantages, including the pharmacokinetic advantage
of their longer half-lives (Kvernmo et al. 2006). In addi-
tion, dopamine-receptor agonists exhibit selectivity in their
binding to dopamine receptors, conceivably permitting a
reduction in the expression of dyskinesias, e.g., by use of
agonists selective for D2-like receptors (Jenner 2008).
Several first-generation agonists (e.g., pergolide, cabergo-
line, and bromocriptine) are ergotamine derivatives asso-
ciated with fibrotic heart disease (Zanettini et al. 2007)
perhaps related to 5-HT(2B) serotonin-receptor agonism
(Antonini and Poewe 2007). In consequence, pergolide has
been withdrawn from the US market; and in the European
Union, the first-generation agents are now restricted to
second-line use (of pergolide and cabergoline) or now
carry warning labels. Despite being ergoline, lisuride lacks
5-HT(2B) agonism and is not known to cause cardiac
valvular fibrosis (Hofmann et al. 2006). Lisuride has been
formulated for transdermal delivery from a skin patch
(which, however, is not widely used, owing to neuropsy-
chiatric complications).
Ropinirole and pramipexole are second-generation,
nonergoline, D2-like-receptor preferring agonists widely
prescribed for oral administration in PD. In their IR forms,
the half-life of ropinirole is *6 h and that of pramipexole
is 8–12 h (Kvernmo et al. 2006). Both drugs are also
available as slow-release formulations. Prolonged-release
(PR) ropinirole is a tablet based on matrix technology.
Compared with the IR formulation given three times daily
(Tompson and Vearer 2007), its once-daily dosing pro-
vided a similar dose-normalized AUC0–24 h, a Cmax 12 %
lower, and a median tmax of approximately 6 versus 2 h for
the IR formulation (Fig. 3a). In a double-blind study in
early PD (Stocchi et al. 2008), it exhibited noninferiority to
ropinirole IR, as judged by unified Parkinson’s disease
rating scale (UPDRS) (Fahn et al. 1987) motor score.
Extended-release (ER) pramipexole is also a matrix tablet.
At steady-state for once-daily dosing (Jenner et al. 2009b),
its Cmax and AUC0–24 h resembled those of the IR formu-
lation given three times daily, but the geometric mean tmax
was more than 5 h versus approximately 1 h for the IR
formulation (Fig. 3b). In a double-blind study in early PD
(Hauser et al. 2010), improvements in UPDRS motor plus
ADL scores resembled those for the IR formulation.
Rotigotine is a nonergoline dopamine agonist selective
for D2-like receptors, but also showing affinity for D1-like
receptors (Scheller et al. 2009). Formulated for transdermal
delivery from skin patches each to be worn for 1 day
(Cawello et al. 2007, 2009; Pfieffer 2005), its availability
has been impeded by problems with crystallization. Nev-
ertheless, a recent large-scale study (Trenkwalder et al.
2011a) in patients selected for having unsatisfactory early
morning motor-symptom control at any PD stage, with or
without levodopa, constitutes the first double-blind, pla-
cebo-controlled investigation of the effects of a CDD
Fig. 2 Plasma levels (a) and motor-function (tapping total) profiles
(b) for slow- versus immediate-release oral levodopa/carbidopa in 18
PD patients with motor fluctuations (data adapted from Pahwa et al.
1997). LC-CR (slow) controlled-release levodopa/carbidopa, LC-IR
immediate-release levodopa/carbidopa
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strategy on both motor and nonmotor deficits. At 12 weeks,
mean early morning motor dysfunction, mean sleep dis-
turbance, and depressive symptomatology [as measured by
UPDRS (Fahn et al. 1987), the PD sleep scale (PDSS)
(Trenkwalder et al. 2011b), and the Beck depression
inventory (BDI) (Visser et al. 2006), respectively] showed
significantly greater improvements in the active-treatment
group. Rotigotine has been re-introduced in the US market
as a new formulation that may be more stable than the
original.
Impulse control disorders such as compulsive gambling,
shopping, or hypersexuality are being increasingly recog-
nized in PD patients as adverse effects of dopamine agonist
therapy (Weintraub and Nirenberg 2013). The degree of
risk associated with long-acting dopamine agonists or in-
fusional dopaminergic therapies is currently under inves-
tigation. A recent post-marketing survey conducted in
Europe has suggested that the risk may be lower for the
rotigotine patch and for pramipexole ER than for shorter-
acting agonists (Rizos et al. 2012).
Continuous drug infusion
Apomorphine and levodopa/carbidopa intestinal gel
(LCIG) are the two dopaminergic therapies currently
available as a continuous infusion for patients with severe
motor fluctuations in advanced PD. Typically, each is
administered during waking hours only. (A third therapy,
lisuride infusion, is not widely used.)
Apomorphine (Apokyn (2012) is a nonergoline dopa-
mine-receptor agonist with less receptor selectivity than
that of other available agonists, although it does demon-
strate some D2-receptor preference (Deleu et al. 2004).
After subcutaneous injection, it is notably short-acting: in
one study, its elimination half-life was 33 min (Gancher
et al. 1989). A portable pump permits its continuous
infusion into subcutaneous fatty tissue of the abdomen,
thighs, or arms (LeWitt 2004); a delivery method available
in Europe. After long-term usage, however, inflammatory
skin nodules may form and may interfere with drug
absorption (Nicolle et al. 1993). In a small study of PD
patients switched from subcutaneous to intravenous apo-
morphine (delivered by indwelling venous catheter) for
refractory motor fluctuations (Manson et al. 2001), dyski-
nesia showed substantial decrease, and ‘‘OFF’’ time was
reported to be virtually eliminated (a mean reduction from
5.4 to 0.5 h; p \ 0.05), although plasma apomorphine
levels did not correlate well with dosage level or with
motor function (Fig. 4a–d), and complication rates were
high. In another small study, of two PD patients, plasma
apomorphine levels likewise showed weak correlation with
motor function, but for cerebrospinal-fluid apomorphine
levels, the correlation with motor function was strong
(Hofstee et al. 1994).
Levodopa/carbidopa intestinal gel (Duodopa; Abbott,
Abbott Park, IL) is a methylcellulose gel suspension of
levodopa/carbidopa formulated for continuous enteral
infusion from a portable pump and medication cassette
worn attached to the waist or over the shoulder (Nyholm
et al. 2003). To complete the delivery system, jejunal or
duodenal tubing is emplaced by a percutaneous endoscopic
gastrostomy procedure. In a small crossover trial (Nyholm
et al. 2003) comparing nasoduodenal LCIG infusion with
optimized sustained-release oral levodopa/carbidopa, the
mean steady-state plasma levodopa concentration was the
same for both the treatments, but the mean Cmax was lower
for LCIG (Fig. 5a, b); and on motor tasks performed at
hourly intervals, a higher proportion of observations were
considered near-normal [at 80 % for LCIG versus 61 %
levodopa/carbidopa CR; estimated mean difference, 19%;
Fig. 3 Plasma levels for PR (a)/ER (b) versus IR formulations of
oral dopamine agonists: Ropinirole (a) in 20 patients with early PD
(data adapted from Tompson and Vearer 2007), and pramipexole
(b) in 14 healthy volunteers (data adapted from Jenner et al. 2009).
ER extended-release, IR immediate-release, PR prolonged-release.
aOnly the last two doses are graphed for pramipexole IR
K. R. Chaudhuri et al.
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95 % confidence interval (CI): 12, 26 %; p \ 0.01]. LCIG
is currently available in Europe, Canada, and Australia and
is under investigation in the United States.
Clinical correlates of CDD
For dopaminergic therapies formulated and/or delivered in
efforts to approach or attain CDD, numerous studies have
evaluated the impact on motor fluctuations and dyskinesia.
Both acute effects and the ability to delay the onset of such
complications have been assessed. The impact on nonmo-
tor function has not yet been evaluated extensively.
Prevention of motor complications in early PD
The most recent practice guidelines for treating early PD
are those of a consensus document published jointly in
2006 by the European Federation of Neurological Societies
(EFNS) and the Movement Disorder Society (MDS)
European Section (Horstink et al. 2006). Based on avail-
able evidence, this panel judged ropinirole and pramipex-
ole, in their IR formulations, to be effective as
monotherapy both for motor-symptom control and for
prevention of levodopa-associated motor complications,
especially among younger patients, in whom such com-
plications are thought to be more likely. For other dopa-
minergic therapies, data either were lacking, as in the case
of COMT inhibitors and the MAO-B inhibitor rasagiline,
or did not support efficacy for motor-complication pre-
vention, as in the case of levodopa CR and the MAO-B
inhibitor selegiline.
Since then, long-term (6-year) data from the CALM-PD
study of levodopa versus pramipexole IR as initial PD
pharmacotherapy have found dopaminergic motor compli-
cations (encompassing ‘‘wearing-off’’, ‘‘ON–OFF’’ effects,
or dyskinesias) to be more likely for levodopa than for the
dopamine agonist (Parkinson Study Group CALM Cohort
Investigators 2009). However, disabling dyskinesias were
uncommon in both treatment groups. Long-term (6.5-year)
data from an open-label extension (Hauser et al. 2009a) of
the TEMPO study (Parkinson Study Group 2004) of early-
versus delayed-start rasagiline have failed to demonstrate a
difference in the median time to development of motor
complications (or time to addition of levodopa) in patients
who started receiving rasagiline 6 months earlier in their
PD than did the delayed-start group. Data have also been
reported concerning the efficacy of COMT inhibitors in
early PD. In the 39-week, double-blind FIRST-STEP study
(Hauser et al. 2009b), the incidence of ‘‘wearing-off’’ and
dyskinesia did not differentiate between groups receiving
levodopa/carbidopa/entacapone (LCE) or only levodopa/
carbidopa three times daily, despite the superiority of LCE
on efficacy measures including the study’s primary out-
come, the sum of motor and ADL scores in the UPDRS (but
not on measures including the motor score alone). STRIDE-
PD (Stocchi et al. 2010), a large-scale, double-blind study
designed specifically to evaluate the capacity of LCE to
Fig. 4 Plasma apomorphine
levels (left y-axis scale) and
simultaneous clinical-state
scores (right y-axis scale) for
each of four recipients of
continuous subcutaneous
apomorphine infusion.
Arrowheads on x-axis mark
bolus doses. Clinical state was a
global objective/subjective
rating in half-point increments,
including ratings of -1 for fully
‘‘OFF’’, 0 for threshold of
‘‘ON’’, ?1 for fully ‘‘ON’’, and
?1.5 for dyskinesia or
subjectively overdosed (e.g.,
light-headed, confused) (data
adapted from Manson et al.
2001)
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delay dyskinesia, has also failed to find such benefit. For
treatment lasting up to 208 weeks, the risk of dyskinesia
was actually higher in the study’s LCE group than in its
levodopa/carbidopa group. Although the mean dosage of
levodopa was highly similar across these groups, the esti-
mated bioavailability of levodopa was significantly
heightened by the entacapone in LCE, conceivably has-
tening dyskinesia (p \ 0.001). The investigators also
hypothesized that the study’s four-times-daily dosing of
LCE (at 3.5-h intervals) might not have achieved CDS.
Two recent meta-analyses (Baker et al. 2009; Stowe
et al. 2008) support the 2006 EFNS/MDS recommenda-
tions on dopamine agonists for prevention of motor com-
plications. For oral IR dopamine-agonist treatment
compared with levodopa, one study (Stowe et al. 2008)
reported an odds ratio (OR) of 0.51 (95 % CI: 0.43, 0.59;
p \ 0.00001) for risk of dyskinesia and 0.75 (95 % CI:
0.63, 0.90; p = 0.002) for risk of motor fluctuations. In the
other study (Baker et al. 2009),while the UPDRS motor
scores demonstrated that patients receiving dopamine
agonists had a significantly inferior response compared
with patients receiving levodopa, based on a [4-point
higher ADL score (weighted mean difference, 4.69; 95 %
CI: 3.76, 5.61; p \ 0.0001), the ORs for risk of dyskinesia
and ‘‘wearing off’’ were 0.36 (95 % CI: 0.22, 0.60;
p \ 0.0001) and 0.52 (95 % CI: 0.40, 0.66; p \ 0.0001),
respectively. Both meta-analyses found that dopamine
agonists conferred an increased risk for somnolence, diz-
ziness, nausea, and hallucinations. In a recent double-blind
study of adding ropinirole PR in levodopa-treated patients
with early PD (Watts et al. 2010), onset of dyskinesia was
significantly delayed in the ropinirole PR group compared
with a group receiving additional levodopa (hazard ratio,
6.46; p \ 0.001). In a head-to-head comparison between
transdermal rotigotine and oral ropinirole IR in early PD
(Giladi et al. 2007), the patch failed to demonstrate non-
inferiority on UPDRS motor plus ADL scores. Differences
in rates of motor complications were not assessed.
Treatment of motor complications in advanced PD
In a literature review published in 2006 (Pahwa et al.
2006), a subcommittee of the American Academy of
Neurology (AAN) concluded that entacapone and rasagi-
line had established their efficacy, and that pramipexole,
ropinirole, and tolcapone were ‘‘probably’’ effective, for
reducing ‘‘OFF’’ time in PD patients with motor fluctua-
tions. For ‘‘OFF’’ time reduction, levodopa/carbidopa CR
was not considered to be more effective than the IR for-
mulation. Continuous-infusion therapies (i.e., apomorphine
or LCIG) were not included in the analyses.
More recent meta-analyses of treatments adjunctive to
levodopa in advanced PD have confirmed the capacities of
oral IR dopamine agonists, COMT inhibitors, and MAO-B
inhibitors to reduce ‘‘OFF’’ time and UPDRS scores. For
all three drug classes, the improvements were at the
expense of an increase in dyskinesia, compared with pla-
cebo (Stowe et al. 2010; Talati et al. 2009). By indirect
comparisons of the three classes, IR dopamine agonists
appeared to be the most effective for reducing ‘‘OFF’’ time
(at -1.54 h/day vs. -0.83 for COMT inhibitors and -0.93
for MAO-B inhibitors), but the agonists (and the COMT
inhibitors) carried a higher risk for dyskinesias than did the
MAO-B inhibitors (Stowe et al. 2010).
In recent studies with placebo control (Pahwa et al. 2007;
Schapira et al. 2011), slow-release oral formulations of
ropinirole and pramipexole, taken adjunctive to levodopa,
have also shown efficacy for reducing ‘‘OFF’’ time and
UPDRS scores. For both agents, ‘‘ON’’ time without trou-
blesome dyskinesia was significantly increased. However,
Fig. 5 Plasma levodopa levels for sustained- (slow-) release oral
levodopa/carbidopa (a) versus continuous intraduodenal infusion of
LCIG (b) in each of 12 patients with advanced PD. In each graph, the
solid black curve with solid black circles for its data points displays
the mean for all curves (data adapted from Nyholm et al. 2003)
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the incidence of dyskinesia as an adverse event was higher
(at 13 % for ropinirole PR vs. 3 % for placebo; and at 17 %
for pramipexole ER vs. 8 % for placebo, a difference not
tested statistically in either trial). In a recent 24-week study
comparing ropinirole formulations (Stocchi et al. 2011), the
slow-release form had a response rate (defined by C20 %
reduction in ‘‘OFF’’ time; adjusted OR, 1.82; 95 % CI: 1.16,
2.86; p = 0.009) and a capacity to reduce UPDRS motor
scores (adjusted mean change from baseline for ropinirole
PR vs IR, -10.2 vs. -7.9, respectively; p = 0.022) sig-
nificantly greater than those for the IR form. The incidence
of adverse events was numerically higher among recipients
of the slow-release form (who also reached higher agonist
dosage, but lower levodopa dosage, than in the IR arm). In
an analogous comparison (Schapira et al. 2011), pramip-
exole ER showed capacities to reduce ‘‘OFF’’ time and
UPDRS motor plus ADL scores resembling those of
pramipexole IR. The incidence of adverse events was
numerically lower for the ER form (at similar agonist
dosage and lower levodopa dosage than in the IR arm).
In each of two studies with placebo control (LeWitt
et al. 2007; Poewe et al. 2007), transdermal rotigotine,
adjunctive to levodopa, has shown efficacy for motor
complications in advanced PD, as evidenced by significant
reductions in ‘‘OFF’’ time (p B 0.0031) and increases in
‘‘ON’’ time without troublesome dyskinesia (p B 0.0078).
Incidence rates for dyskinesia as an adverse event were
higher for rotigotine than for placebo (but were not tested
statistically). In one of these studies (Poewe et al. 2007), a
third treatment arm permitted head-to-head comparisons
between the rotigotine patch and pramipexole IR.
Improvements in ‘‘OFF’’ time, ‘‘ON’’ time without trou-
blesome dyskinesias, and other outcomes showed no sig-
nificant differences between these two treatments.
No double-blind studies have yet been reported for
chronic treatment with apomorphine. However, in 2004 a
review of 11 long-term, uncontrolled, open-label studies of
subcutaneous apomorphine infusion (Deleu et al. 2004)
reported a 60 % mean reduction in ‘‘OFF’’ time (range
50–80 % across studies) and also improvement in dyskine-
sia, which, however, required a mean of 12 months (range
0.5–50 months) to reach its maximum. Two further studies
of subcutaneous apomorphine infusion have since been
reported. In a prospective study (Katzenschlager et al. 2005),
12 patients with motor fluctuations and disabling dyskinesias
received apomorphine infusion for 6 months. ‘‘OFF’’ time
was reduced from baseline by 38 % (p \ 0.05) and dyski-
nesia duration by 40 % (p \ 0.01). In four of the 12 patients,
oral medication could be discontinued, and within this
apomorphine monotherapy group, there was a significantly
greater decrease in ‘‘OFF’’ time and dyskinesia severity and
duration than in the polytherapy group (for ‘‘OFF’’ time, 64
vs. 18 %, respectively, p \ 0.05; for dyskinesia severity and
duration expressed as centimeters on a visual analogue scale,
8.6 vs. 19.8, respectively, p \ 0.05). Skin nodules were
reported in 11 of 12 patients, including two patients with skin
changes and inflammatory reactions requiring rotation of the
infusion site. A retrospective analysis (Garcı´a-Ruiz et al.
2008) of 82 patients who tolerated subcutaneous apomor-
phine infusion for at least 3 months (mean, 20 months) also
identified significant decreases from baseline in ‘‘OFF’’
time (mean baseline vs. last follow-up visit, 6.64 vs.
1.36 h/waking day, p \ 0.0001) and dyskinesia severity
score (1.65 vs. 1.15, respectively, p \ 0.0006). In this study,
68 % of patients reported treatment-related skin nodules.
For LCIG, findings of a double-blind, double-dummy
trial comparing intrajejunal gel infusion and oral admin-
istration of levodopa-carbidopa in IR form have now been
presented. For 12 weeks, PD patients selected for having
motor complications underwent active LCIG infusion and
took placebo IR capsules or took active IR capsules and
underwent placebo gel infusion (Olanow et al. 2011).
Among 66 study completers (93 % of the 71 randomized
subjects), decrease in ‘‘OFF’’ time and increase in ‘‘ON’’
time without troublesome dyskinesia favored LCIG by
means of -1.91 and ?1.86 h/d, respectively, while ‘‘ON’’
time with troublesome dyskinesia showed no significant
change (Olanow et al. 2012). Significant global, functional
(ADL), and quality-of-life LCIG benefits were also iden-
tified (Kieburtz et al. 2012).
Several previous, open-label studies had already evalu-
ated LCIG during chronic treatment lasting up to 7 years
(Table 1) (Antonini et al. 2007, 2008, 2010b; Eggert et al.
2008; Isacson et al. 2008; Nilsson et al. 2001). Although
variations in trial design preclude any summarization of the
numerical findings, measures of ‘‘OFF’’ time improved in
all six studies, with significance achieved in all five studies
in which statistical testing was performed; dyskinesia
measures also improved in all six studies, with statistical
significance in four of the five studies with statistical
testing. In addition, a randomized crossover trial (Nyholm
et al. 2005) has compared 3 weeks of individually opti-
mized conventional treatment with 3 weeks of nasoduo-
denal LCIG infusion. The conventional treatment was oral
levodopa/carbidopa in optional combinations with oral
dopamine agonists, COMT-inhibitors, MAO-B inhibitors,
amantadine, or subcutaneous apomorphine (by injections
or infusion). Motor tasks were videotaped every 30 min for
8 h on 2 days during the second and third week of each
treatment for rating of motor function by neurologists
blinded to treatment identity. (To blind the conventional
therapies, a dummy nasogastric tube was emplaced.) Of 24
enrolled patients, 20 completed conventional therapy and
21 completed LCIG. The mean percentage of ratings fall-
ing within the predefined range for a clinically desirable
‘‘ON’’ state was significantly greater during LCIG than
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during conventional therapy (at 90.7 vs. 74.5 %, respec-
tively, p \ 0.01), and the mean percentage of ratings of
‘‘OFF’’ state was significantly lower (at 1.8 vs. 19.2 %,
respectively, p \ 0.01). For ratings of ‘‘ON’’ with moder-
ate-to-severe dyskinesia, LCIG and conventional therapy
showed no significant difference. Of the four patients who
received subcutaneous apomorphine infusion as part of
their conventional therapy, two were rated as being in an
‘‘ON’’ state all or nearly all of the time on both conven-
tional treatment and LCIG, but the other two had sub-
stantial improvements on LCIG. In one patient, the
proportion of ‘‘ON’’ ratings improved from 56 to 94 %,
and in the other from 68 to 100 %.
The most common adverse events leading to discon-
tinuation of chronic LCIG treatment have been related to
medication delivery, including problems with tubing dis-
placement or occlusion, the pump system, and stoma
infections (Antonini et al. 2007, 2008, 2010b; Eggert et al.
2008; Nilsson et al. 2001). To monitor long-term safety,
close observation is warranted, as guided by recent reports
of neuropathy associated with homocysteine elevation and
at least functional vitamin B12 and/or B6 deficiency
(Klostermann et al. 2012).
Treatment of nonmotor symptoms
In general, published management recommendations for
nonmotor PD symptoms have not attempted to differentiate
between symptoms intrinsic to PD and those arising as
complications of PD therapy. A contributory problem may
be that in clinical studies of dopaminergic options,
improvement of nonmotor PD symptoms, levodopa-related
or not, has seldom been either a primary endpoint or a
means for comparing treatments with potentially different
abilities to produce CDD. In a double-blind, 12-week,
parallel-group study of patients with early PD (Fung et al.
2009), oral LCE was superior to levodopa/carbidopa for
improving quality of life, as rated by total score on the
eight-item PDQ (PDQ-8) (Jenkinson et al. 1997b) and by
subscores for the PDQ-8 nonmotor domains of depression,
personal relationships, communication, and stigma. In a
small single-dose, crossover study of oral levodopa/carbi-
dopa CR versus IR (Kulisevsky et al. 2007), the seven PD
patients with ‘‘wearing-off’’ showed significant mood
improvement after IR treatment, while the seven nonfluc-
tuating patients showed no mood improvement after
receiving either drug. Plasma levodopa concentration cor-
related with anxiety level but not with mood.
Transdermal rotigotine has recently been assessed ver-
sus placebo in a large, double-blind trial (Trenkwalder
et al. 2011a) in PD patients with unsatisfactory early
morning motor-symptom control. On the PDSS-2 (Tren-
kwalder et al. 2011b), the mean 12-week change in total
score (a coprimary outcome) was significantly improved in
the rotigotine group compared with placebo from baseline
to end of maintenance [least squares (LS) mean treatment
difference, -4.26; 95 % CI: -6.08, -2.45; p \ 0.0001].
Difficulty in falling asleep and feeling tired and sleepy in
the morning were among the ten items showing significant
improvement (among the instrument’s total of 15). Sig-
nificant improvement versus placebo was also documented
for mean change in total score on the NMSS (Martinez-
Martin et al. 2009) from baseline to end of treatment
(LS mean treatment difference, -6.65; 95 % CI: -11.99,
-1.31; p = 0.015), with significant changes on the sleep/
fatigue and the mood/cognition domains (LS mean
Table 1 ‘‘OFF’’ time and dyskinesia outcomes in prospective studies of long-term LCIG therapy
Study N enrolled/
n completed
Maximum
duration
Outcome versus conventional treatment
Nilsson et al. (2001) 9/6a 7 years ‘‘OFF’’ time duration decreased at 3–8 months and at 4–7 yearsb. Dyskinesia
duration decreased at 3–8 months and further decreased at 4–7 years
Antonini et al. (2007) 9/7 1 year ‘‘OFF’’ time and disabling-dyskinesia duration significantly decreased
Antonini et al. (2008) 22/17 2 years ‘‘OFF’’-time duration and severity (by UPDRS part IV) significantly decreased
Eggert et al. (2008) 13/11 6 monthsc ‘‘OFF’’ time and ‘‘ON’’ time with disabling dyskinesia significantly reduced as
percent of patient’s day
Isacson et al. (2008)d 14/12 6 months Proportion of patients with reduced ‘‘OFF’’ time significantly greater; proportion
with reduced dyskinesia numerically greater
Antonini et al. (2010b) 15/4 3 years ‘‘OFF’’ time duration and dyskinesia severity (by UPDRS part IV) significantly
decreased
LCIG levodopa/carbidopa intestinal gel, UPDRS unified Parkinson’s disease rating scale
a Six patients had video scoring of motor state at both of two time points. Changes were not tested statistically
b Excludes one patient at the final time point, who was considered ‘‘OFF’’ at all video recordings
c Some patients continued for up to 12 months
d Extension of Nyholm et al. (2005) crossover trial
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treatment differences of -2.03; 95 % CI: -3.31, -0.75;
p = 0.002 and -3.40; 95 % CI: -5.22, -1.58; p =
0.0003, respectively), and on the BDI-II depressive-
symptomatology scale (Visser et al. 2006) from baseline to
end of treatment (LS mean treatment difference, -2.01;
95 % CI: -3.55, -0.47; p = 0.011).
Improvement of nonmotor PD symptoms by subcuta-
neous apomorphine infusion has been a primary endpoint
in two small prospective trials (Martinez-Martin et al.
2010; Reuter et al. 1999). In six patients with refractory
nocturnal symptoms (Reuter et al. 1999), continuous
overnight infusion (with placebo control in three of the
subjects) was associated with decreases in awakenings,
dystonia, pain, and nocturia. In an open-label trial (Marti-
nez-Martin et al. 2010), 17 patients with advanced PD
received subcutaneous apomorphine infusion and 17
received conventional therapy. At approximately 6 months,
NMSS and PDQ-8 total scores showed significant
improvement from baseline in the apomorphine group but
did not change in the conventional-therapy group.
Improvement of nonmotor PD symptoms by intraduo-
denal LCIG infusion was the primary endpoint in a pro-
spective, open-label trial conducted in 22 patients with daily
motor fluctuations and dyskinesia refractory to optimized
conventional therapy with oral medications, transdermal
rotigotine, or subcutaneous apomorphine infusion (Honig
et al. 2009). After discontinuation of the conventional
therapy (except for nighttime oral dosing with levodopa CR
or a long-acting dopamine agonist) and its replacement by
LCIG for a mean of 6.7 months, mean change in NMSS
total score showed significant improvement from baseline
(-50.5, p = 0.0001). Of the nine NMSS domains, six
were significantly improved [cardiovascular (-2.41, p =
0.0004), sleep/fatigue (-11.32, p = 0.0001), attention/
memory (-3.27, p = 0.002), gastrointestinal (-6.23,
p = 0.0003), urinary (-6.64, p = 0.002), and miscella-
neous (-7.73, p = 0.0004)]. The change in total NMSS
score was correlated with changes on measures of motor
function [UPDRS motor-complication score (-5.91, p =
0.0000), UPDRS dyskinesia subscore (-3.7, p = 0.0001),
and ‘‘OFF’’ time as a proportion of the waking day
(r = 0.54, p \ 0.01)]. On the PDSS and PDQ-8, mean
improvement in total score was also significant (?28.51;
p = 0.002 and -23.4; p = 0.0003, respectively).
Conclusions
For several decades, the pharmacologic treatment of PD
has been evolving, most recently in a quest to achieve CDS
or, more verifiably, CDD. Improvements in the steadiness
of the plasma concentration-versus-time profiles of various
dopaminergic therapies (Fig. 6) may be a signal of pro-
gress. However, improvements in plasma profile do not
necessarily translate into a more continuous stimulation of
central dopamine receptors. To directly evaluate the degree
of CDS that a dopaminergic drug may confer, studies
assessing dopamine-receptor occupancy (as measured,
e.g. by brain imaging) will be necessary (Brooks et al.
2010).
Fig. 6 Variability in the plasma level of various formulations of
dopaminergic therapies. Coefficient of variation (CV) (a)—the
standard deviation in plasma level, expressed as a percentage of
group geometric mean plasma level—for oral immediate-release
levodopa/carbidopa/entacapone versus levodopa/carbidopa (LCE vs.
LC), oral slow- versus immediate-release levodopa/carbidopa (LC-
CR vs. LC), and intraduodenal levodopa/carbidopa intestinal gel
versus oral slow-release levodopa/carbidopa (LCIG vs. LC-CR).
Peak-to-trough fluctuation (PTF) (b)—Cmax - Cmin, expressed as a
percentage of group geometric mean plasma level—for oral slow-
versus immediate-release ropinirole (RPR-XL vs. RPR-IR), oral
slow- versus immediate-release pramipexole (PPX-ER vs. PPX-IR),
and transdermal rotigotine (RTG). CR controlled-release, ER and XL
extended-release
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So far, clinical studies of efforts to improve PD motor
symptoms using therapies expected to provide more CDS
have generally been positive, including double-blind, ran-
domized trials with placebo control. However, the findings
of studies comparing differing active treatments have often
failed to find evidence favoring these approaches over an
intermittent therapy. In such trials, levodopa/carbidopa CR,
for example, was not superior to levodopa/carbidopa IR in
advanced PD (Pahwa et al. 2006); LCE was not superior to
levodopa/carbidopa, at least for delaying motor complica-
tions in early PD (Stocchi et al. 2010); pramipexole ER
was not superior to pramipexole IR as an adjunct to levo-
dopa in advanced PD (Schapira et al. 2011); and trans-
dermal rotigotine was not superior either to IR ropinirole as
monotherapy in early PD (Giladi et al. 2007) or to IR
pramipexole as an adjunct to levodopa in advanced PD
(Poewe et al. 2007). A conceivable explanation for the lack
of substantial difference may be that the so-called standard-
release dopamine agonists in fact have ‘‘longish’’ half-lives
compared with levodopa IR and even with levodopa CR.
By a similar argument, continuous agonist delivery using
transdermal rotigotine would lack superiority to IR ropin-
irole because the half-life of the oral IR agent is already
fairly long. However, transdermal rotigotine is not as
effective as the infusional dopaminergic therapies (apo-
morphine or levodopa), suggesting that the inherent
potency of each agent is also determinative. In studies of
differing formulations of the same agent, i.e., levodopa, the
longer-acting formulation has shown superior benefit
(Hauser 2012). For their part, the infusional therapies
presumably gain from accessing the blood stream without
need for gastric transit. Currently, apomorphine is the only
dopamine agonist rivaling levodopa in potency, and its
half-life is shorter. In the MPTP primate PD model, its
intermittent administration shares with levodopa a capacity
to induce dyskinesia, but in the same model, animals
undergoing continuous subcutaneous apomorphine infu-
sion for up to 6 months did not become dyskinetic (Bib-
biani et al. 2005). In PD patients, moreover, continuous
apomorphine infusion has been found to downregulate
preexisting dyskinesia (Colzi et al. 1998; Katzenschlager
et al. 2005).
Clinical studies focusing on improving nonmotor PD
symptoms are becoming more common. These trials, too,
have not yet clarified any potential differences across
therapies with differing capacities for CDD. Nevertheless,
the findings of nonmotor improvement among recipients of
subcutaneous apomorphine (Martinez-Martin et al. 2010)
or intrajejunal LCIG (Honig et al. 2009) suggest that
nonmotor PD symptoms or complications may improve in
tandem with the expected motor improvements. For more
persistent nonmotor problems, nondopaminergic treat-
ments seem likely to remain key (Zesiewicz et al. 2010).
Here, too, future research should explore drug activity at
dopaminergic synapses, so as to determine whether CDS is,
in fact, an important determinant of clinical efficacy.
Certainly, the complexities of optimal PD management,
and the rationale for an underlying strategy such as CDS or
CDD, have not yet been thoroughly elucidated.
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